Dr. Steven M. Horwitz, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Lymphoma
Studies T-Cell Lymphoma
12 reported clinical trials
18 drugs studied
Area of expertise
1Lymphoma
Stage I
Stage IV
HTLV-1 positive
2T-Cell Lymphoma
Stage I
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Steven M. Horwitz, MD is currently running
Lenalidomide + EPOCH Chemotherapy
for Adult T-Cell Leukemia-Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.
Recruiting1 award Phase 1
Mogamulizumab
for Preventing Adult T-Cell Leukemia/Lymphoma
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Recruiting1 award Phase 25 criteria
More about Steven M. Horwitz, MD
Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Steven M. Horwitz, MD has experience with
- Duvelisib
- Mogamulizumab
- Prednisone
- Lenalidomide
- Ruxolitinib
- Bortezomib
Breakdown of trials Steven M. Horwitz, MD has run
Lymphoma
T-Cell Lymphoma
Relapse
Peripheral T-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven M. Horwitz, MD specialize in?
Steven M. Horwitz, MD focuses on Lymphoma and T-Cell Lymphoma. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage IV.
Is Steven M. Horwitz, MD currently recruiting for clinical trials?
Yes, Steven M. Horwitz, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Steven M. Horwitz, MD has studied deeply?
Yes, Steven M. Horwitz, MD has studied treatments such as Duvelisib, Mogamulizumab, Prednisone.
What is the best way to schedule an appointment with Steven M. Horwitz, MD?
Apply for one of the trials that Steven M. Horwitz, MD is conducting.
What is the office address of Steven M. Horwitz, MD?
The office of Steven M. Horwitz, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.